Roland W.R.W.FreudenmannRoland W.R.W., FlorianF.OxlerFlorianF., SabineS.Bernschneider-ReifSabineS., The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents, „Addiction”, 101 (9), 2006, s. 1241–1245, DOI: 10.1111/j.1360-0443.2006.01511.x, PMID: 16911722 [dostęp 2021-02-03](ang.).
DavidD.NuttDavidD. i inni, Development of a rational scale to assess the harm of drugs of potential misuse, „The Lancet”, 369 (9566), 2007, s. 1047–1053, DOI: 10.1016/S0140-6736(07)60464-4, PMID: 17382831 [dostęp 2021-02-03](ang.).
M.E.M.E.LiechtiM.E.M.E., A.A.GammaA.A., F.X.F.X.VollenweiderF.X.F.X., Gender differences in the subjective effects of MDMA, „Psychopharmacology”, 154 (2), 2001, s. 161–168, DOI: 10.1007/s002130000648, PMID: 11314678 [dostęp 2021-02-03](ang.).
Keith R.K.R.LawsKeith R.K.R., JoyJ.KokkalisJoyJ., Ecstasy (MDMA) and memory function: a meta-analytic update, „Human Psychopharmacology”, 22 (6), 2007, s. 381–388, DOI: 10.1002/hup.857, PMID: 17621368 [dostęp 2022-11-09].
Gregory M.G.M.MillerGregory M.G.M., The Emerging Role of Trace Amine Associated Receptor 1 in the Functional Regulation of Monoamine Transporters and Dopaminergic Activity, „Journal of neurochemistry”, 116 (2), 2011, s. 164–176, DOI: 10.1111/j.1471-4159.2010.07109.x, PMID: 21073468, PMCID: PMC3005101 [dostęp 2021-02-03](ang.).
J.L.J.L.FitzgeraldJ.L.J.L., J.J.J.J.ReidJ.J.J.J., Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices, „European Journal of Pharmacology”, 191 (2), 1990, s. 217–220, DOI: 10.1016/0014-2999(90)94150-v, PMID: 1982265 [dostęp 2021-02-03](ang.).
Inger LiseI.L.BogenInger LiseI.L. i inni, Short- and long-term effects of MDMA („ecstasy”) on synaptosomal and vesicular uptake of neurotransmitters in vitro and ex vivo, „Neurochemistry International”, 43 (4–5), 2003, s. 393–400, DOI: 10.1016/s0197-0186(03)00027-5, PMID: 12742084 [dostęp 2021-02-03](ang.).
Mark D.M.D.BerryMark D.M.D. i inni, Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges, „Pharmacology & Therapeutics”, 180, 2017, s. 161–180, DOI: 10.1016/j.pharmthera.2017.07.002, PMID: 28723415 [dostęp 2021-02-03](ang.).
G.G.BattagliaG.G. i inni, Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites, „European Journal of Pharmacology”, 149 (1–2), 1988, s. 159–163, DOI: 10.1016/0014-2999(88)90056-8, PMID: 2899513 [dostęp 2021-02-03](ang.).
R.A.R.A.LyonR.A.R.A., R.A.R.A.GlennonR.A.R.A., M.M.TitelerM.M., 3,4-Methylenedioxymethamphetamine (MDMA): stereoselective interactions at brain 5-HT1 and 5-HT2 receptors, „Psychopharmacology”, 88 (4), 1986, s. 525–526, DOI: 10.1007/BF00178519, PMID: 2871581 [dostęp 2021-02-03](ang.).
J.F.J.F.NashJ.F.J.F. i inni, Effect of the R(–) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors, „Neuroscience Letters”, 177 (1–2), 1994, s. 111–115, DOI: 10.1016/0304-3940(94)90057-4, PMID: 7824160 [dostęp 2021-02-03](ang.).
VincentV.SetolaVincentV. i inni, 3,4-methylenedioxymethamphetamine (MDMA, „Ecstasy”) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro, „Molecular Pharmacology”, 63 (6), 2003, s. 1223–1229, DOI: 10.1124/mol.63.6.1223, PMID: 12761331 [dostęp 2021-02-03](ang.).
FelixF.BetzlerFelixF., LeonardL.ViohlLeonardL., NinaN.Romanczuk-SeiferthNinaN., Decision-making in chronic ecstasy users: a systematic review, „The European Journal of Neuroscience”, 45 (1), 2017, s. 34–44, DOI: 10.1111/ejn.13480, PMID: 27859780 [dostęp 2021-02-03](ang.).
Michael C.M.C.MithoeferMichael C.M.C. i inni, 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial, „The Lancet. Psychiatry”, 5 (6), 2018, s. 486–497, DOI: 10.1016/S2215-0366(18)30135-4, PMID: 29728331 [dostęp 2021-02-03](ang.).
Roland W.R.W.FreudenmannRoland W.R.W., FlorianF.OxlerFlorianF., SabineS.Bernschneider-ReifSabineS., The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents, „Addiction”, 101 (9), 2006, s. 1241–1245, DOI: 10.1111/j.1360-0443.2006.01511.x, PMID: 16911722 [dostęp 2021-02-03](ang.).
DavidD.NuttDavidD. i inni, Development of a rational scale to assess the harm of drugs of potential misuse, „The Lancet”, 369 (9566), 2007, s. 1047–1053, DOI: 10.1016/S0140-6736(07)60464-4, PMID: 17382831 [dostęp 2021-02-03](ang.).
M.E.M.E.LiechtiM.E.M.E., A.A.GammaA.A., F.X.F.X.VollenweiderF.X.F.X., Gender differences in the subjective effects of MDMA, „Psychopharmacology”, 154 (2), 2001, s. 161–168, DOI: 10.1007/s002130000648, PMID: 11314678 [dostęp 2021-02-03](ang.).
Keith R.K.R.LawsKeith R.K.R., JoyJ.KokkalisJoyJ., Ecstasy (MDMA) and memory function: a meta-analytic update, „Human Psychopharmacology”, 22 (6), 2007, s. 381–388, DOI: 10.1002/hup.857, PMID: 17621368 [dostęp 2022-11-09].
Gregory M.G.M.MillerGregory M.G.M., The Emerging Role of Trace Amine Associated Receptor 1 in the Functional Regulation of Monoamine Transporters and Dopaminergic Activity, „Journal of neurochemistry”, 116 (2), 2011, s. 164–176, DOI: 10.1111/j.1471-4159.2010.07109.x, PMID: 21073468, PMCID: PMC3005101 [dostęp 2021-02-03](ang.).
J.L.J.L.FitzgeraldJ.L.J.L., J.J.J.J.ReidJ.J.J.J., Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices, „European Journal of Pharmacology”, 191 (2), 1990, s. 217–220, DOI: 10.1016/0014-2999(90)94150-v, PMID: 1982265 [dostęp 2021-02-03](ang.).
Inger LiseI.L.BogenInger LiseI.L. i inni, Short- and long-term effects of MDMA („ecstasy”) on synaptosomal and vesicular uptake of neurotransmitters in vitro and ex vivo, „Neurochemistry International”, 43 (4–5), 2003, s. 393–400, DOI: 10.1016/s0197-0186(03)00027-5, PMID: 12742084 [dostęp 2021-02-03](ang.).
Mark D.M.D.BerryMark D.M.D. i inni, Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges, „Pharmacology & Therapeutics”, 180, 2017, s. 161–180, DOI: 10.1016/j.pharmthera.2017.07.002, PMID: 28723415 [dostęp 2021-02-03](ang.).
H.H.KalantH.H., The pharmacology and toxicology of „ecstasy” (MDMA) and related drugs, „Canadian Medical Association Journal”, 165 (7), 2001, s. 917–928, PMID: 11599334, PMCID: PMC81503 [dostęp 2021-02-03](ang.).
G.G.BattagliaG.G. i inni, Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites, „European Journal of Pharmacology”, 149 (1–2), 1988, s. 159–163, DOI: 10.1016/0014-2999(88)90056-8, PMID: 2899513 [dostęp 2021-02-03](ang.).
R.A.R.A.LyonR.A.R.A., R.A.R.A.GlennonR.A.R.A., M.M.TitelerM.M., 3,4-Methylenedioxymethamphetamine (MDMA): stereoselective interactions at brain 5-HT1 and 5-HT2 receptors, „Psychopharmacology”, 88 (4), 1986, s. 525–526, DOI: 10.1007/BF00178519, PMID: 2871581 [dostęp 2021-02-03](ang.).
J.F.J.F.NashJ.F.J.F. i inni, Effect of the R(–) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors, „Neuroscience Letters”, 177 (1–2), 1994, s. 111–115, DOI: 10.1016/0304-3940(94)90057-4, PMID: 7824160 [dostęp 2021-02-03](ang.).
VincentV.SetolaVincentV. i inni, 3,4-methylenedioxymethamphetamine (MDMA, „Ecstasy”) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro, „Molecular Pharmacology”, 63 (6), 2003, s. 1223–1229, DOI: 10.1124/mol.63.6.1223, PMID: 12761331 [dostęp 2021-02-03](ang.).
FelixF.BetzlerFelixF., LeonardL.ViohlLeonardL., NinaN.Romanczuk-SeiferthNinaN., Decision-making in chronic ecstasy users: a systematic review, „The European Journal of Neuroscience”, 45 (1), 2017, s. 34–44, DOI: 10.1111/ejn.13480, PMID: 27859780 [dostęp 2021-02-03](ang.).
Michael C.M.C.MithoeferMichael C.M.C. i inni, 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial, „The Lancet. Psychiatry”, 5 (6), 2018, s. 486–497, DOI: 10.1016/S2215-0366(18)30135-4, PMID: 29728331 [dostęp 2021-02-03](ang.).